Royalty Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two upcoming investor conferences. The events include the SVB Securities Global Biopharma Conference on February 16 at 10:40 a.m. ET and the Cowen 43rd Annual Health Care Conference on March 7 at 11:10 a.m. ET. The webcasts for these conferences will be available on Royalty Pharma’s Events page and will remain accessible for at least thirty days after the events. Royalty Pharma, founded in 1996, is a leader in biopharmaceutical royalty acquisition and funding innovation in the industry, boasting a portfolio exceeding 35 commercial products. For more details, visit their official website.

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and March:

• SVB Securities Global Biopharma Conference on Thursday, February 16 at 10:40 a.m. ET
• Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 11:10 a.m. ET

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to cofund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates. For more information, visit www.royaltypharma.com.   

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What investor conferences is Royalty Pharma (RPRX) attending in February and March 2023?

Royalty Pharma will participate in the SVB Securities Global Biopharma Conference on February 16, 2023, and the Cowen 43rd Annual Health Care Conference on March 7, 2023.

When is the SVB Securities Global Biopharma Conference for Royalty Pharma (RPRX)?

The SVB Securities Global Biopharma Conference is scheduled for February 16, 2023, at 10:40 a.m. ET.

What time is Royalty Pharma's presentation at the Cowen 43rd Annual Health Care Conference?

Royalty Pharma's presentation at the Cowen 43rd Annual Health Care Conference will take place on March 7, 2023, at 11:10 a.m. ET.

Where can I access the webcasts for Royalty Pharma (RPRX) investor conferences?

The webcasts for Royalty Pharma’s investor conferences can be accessed on their Events page on the company's official website.

How long will the webcasts for Royalty Pharma's conferences be available?

The webcasts from Royalty Pharma's investor conferences will be archived for a minimum of thirty days.